Advertisement

Multiple Myeloma

  • A transplant “immunome” screening platform defines a targetable epitope fingerprint of multiple myeloma
    Aneta Schieferdecker, Anna Oberle, Benjamin Thiele, Fabian Hofmann, Markus Göthel, Sebastian Miethe, Michael Hust, Friederike Braig, Mareike Voigt, Ute-Marie von Pein, Friedrich Koch-Nolte, Friedrich Haag, Malik Alawi, Daniela Indenbirken, Adam Grundhoff, Carsten Bokemeyer, Ulrike Bacher, Nicolaus Kröger and Mascha Binder
  • Minimal residual disease monitoring and immune profiling in multiple myeloma in elderly patients
    Bruno Paiva, Maria-Teresa Cedena, Noemi Puig, Paula Arana, Maria-Belen Vidriales, Lourdes Cordon, Juan Flores-Montero, Norma C. Gutierrez, María-Luisa Martín-Ramos, Joaquin Martinez-Lopez, Enrique M. Ocio, Miguel T. Hernandez, Ana-Isabel Teruel, Laura Rosiñol, María-Asunción Echeveste, Rafael Martinez, Mercedes Gironella, Albert Oriol, Carmen Cabrera, Jesus Martin, Joan Bargay, Cristina Encinas, Yolanda Gonzalez, Jacques J. M. Van Dongen, Alberto Orfao, Joan Bladé, Maria-Victoria Mateos, Juan José Lahuerta and Jesús F. San Miguel
  • Treatment of multiple myeloma with high-risk cytogenetics: a consensus of the International Myeloma Working Group
    Pieter Sonneveld, Hervé Avet-Loiseau, Sagar Lonial, Saad Usmani, David Siegel, Kenneth C. Anderson, Wee-Joo Chng, Philippe Moreau, Michel Attal, Robert A. Kyle, Jo Caers, Jens Hillengass, Jesús San Miguel, Niels W. C. J. van de Donk, Hermann Einsele, Joan Bladé, Brian G. M. Durie, Hartmut Goldschmidt, María-Victoria Mateos, Antonio Palumbo and Robert Orlowski
  • First report of MYD88 L265P somatic mutation in IgM-associated light-chain amyloidosis
    Rajshekhar Chakraborty, Anne J. Novak, Stephen M. Ansell, Eli Muchtar, Prashant Kapoor, Suzanne R. Hayman, Angela Dispenzieri, Francis K. Buadi, Martha Q. Lacy, Rebecca L. King and Morie A. Gertz
  • Randomized phase 2 study: elotuzumab plus bortezomib/dexamethasone vs bortezomib/dexamethasone for relapsed/refractory MM
    Andrzej Jakubowiak, Massimo Offidani, Brigitte Pégourie, Javier De La Rubia, Laurent Garderet, Kamel Laribi, Alberto Bosi, Roberto Marasca, Jacob Laubach, Ann Mohrbacher, Angelo Michele Carella, Anil K. Singhal, L. Claire Tsao, Mark Lynch, Eric Bleickardt, Ying-Ming Jou, Michael Robbins and Antonio Palumbo
  • Phase 1 study of marizomib in relapsed or relapsed and refractory multiple myeloma: NPI-0052-101 Part 1
    Paul G. Richardson, Todd M. Zimmerman, Craig C. Hofmeister, Moshe Talpaz, Asher A. Chanan-Khan, Jonathan L. Kaufman, Jacob P. Laubach, Dharminder Chauhan, Andrzej J. Jakubowiak, Steven Reich, Mohit Trikha and Kenneth C. Anderson
  • Randomized multicenter phase 2 study of pomalidomide, cyclophosphamide, and dexamethasone in relapsed refractory myeloma
    Rachid C. Baz, Thomas G. Martin III, Hui-Yi Lin, Xiuhua Zhao, Kenneth H. Shain, Hearn J. Cho, Jeffrey L. Wolf, Anuj Mahindra, Ajai Chari, Daniel M. Sullivan, Lisa A. Nardelli, Kenneth Lau, Melissa Alsina and Sundar Jagannath
  • VTD is superior to VCD prior to intensive therapy in multiple myeloma: results of the prospective IFM2013-04 trial
    Philippe Moreau, Cyrille Hulin, Margaret Macro, Denis Caillot, Carine Chaleteix, Murielle Roussel, Laurent Garderet, Bruno Royer, Sabine Brechignac, Mourad Tiab, Mathieu Puyade, Martine Escoffre, Anne-Marie Stoppa, Thierry Facon, Brigitte Pegourie, Driss Chaoui, Arnaud Jaccard, Borhane Slama, Gerald Marit, Karim Laribi, Pascal Godmer, Odile Luycx, Jean-Claude Eisenmann, Olivier Allangba, Mamoun Dib, Carla Araujo, Jean Fontan, Karim Belhadj, Marc Wetterwald, Véronique Dorvaux, Jean-Paul Fermand, Philippe Rodon, Brigitte Kolb, Sylvie Glaisner, Jean-Valere Malfuson, Pascal Lenain, Laetitia Biron, Lucie Planche, Helene Caillon, Herve Avet-Loiseau, Thomas Dejoie and Michel Attal
  • MUC1-C drives MYC in multiple myeloma
    Ashujit Tagde, Hasan Rajabi, Audrey Bouillez, Maroof Alam, Reddy Gali, Shannon Bailey, Yu-Tzu Tai, Teru Hideshima, Kenneth Anderson, David Avigan and Donald Kufe
  • Beyond the plasma cell: emerging therapies for immunoglobulin light chain amyloidosis
    Brendan M. Weiss, Sandy W. Wong and Raymond L. Comenzo

Pages